Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Common Equity (2023 - 2025)

Historic Common Equity for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $687.6 million.

  • CG Oncology's Common Equity rose 2810.76% to $687.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $687.6 million, marking a year-over-year increase of 2810.76%. This contributed to the annual value of $733.4 million for FY2024, which is 69575.71% up from last year.
  • Latest data reveals that CG Oncology reported Common Equity of $687.6 million as of Q3 2025, which was up 2810.76% from $670.4 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Common Equity ranged from a high of $733.4 million in Q4 2024 and a low of -$123.1 million during Q4 2023
  • Its 3-year average for Common Equity is $541.4 million, with a median of $619.6 million in 2024.
  • In the last 5 years, CG Oncology's Common Equity skyrocketed by 69575.71% in 2024 and then skyrocketed by 2136.27% in 2025.
  • Quarter analysis of 3 years shows CG Oncology's Common Equity stood at -$123.1 million in 2023, then surged by 695.76% to $733.4 million in 2024, then dropped by 6.24% to $687.6 million in 2025.
  • Its Common Equity stands at $687.6 million for Q3 2025, versus $670.4 million for Q2 2025 and $704.8 million for Q1 2025.